Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-17-005355
Filing Date
2017-05-15
Accepted
2017-05-15 17:05:57
Documents
64
Period of Report
2017-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm 10-Q 584093
2 ex10-1.htm EX-10.1 180815
3 ex10-2.htm EX-10.2 56396
4 ex31-1.htm EX-31.1 16768
5 ex31-2.htm EX-31.2 16872
6 ex32-1.htm EX-32.1 6791
7 ex32-2.htm EX-32.2 6626
8 image_001.jpg GRAPHIC 81205
  Complete submission text file 0001493152-17-005355.txt   3584634

Data Files

Seq Description Document Type Size
9 XBRL INSTANCE FILE heb-20170331.xml EX-101.INS 535833
10 XBRL SCHEMA FILE heb-20170331.xsd EX-101.SCH 46614
11 XBRL CALCULATION FILE heb-20170331_cal.xml EX-101.CAL 44843
12 XBRL DEFINITION FILE heb-20170331_def.xml EX-101.DEF 154828
13 XBRL LABEL FILE heb-20170331_lab.xml EX-101.LAB 314935
14 XBRL PRESENTATION FILE heb-20170331_pre.xml EX-101.PRE 218677
Mailing Address 1617 JFK BLVD, SUITE #500 ONE PENN CENTER PHILADELPHIA PA 19103
Business Address 1617 JFK BLVD, SUITE #500 ONE PENN CENTER PHILADELPHIA PA 19103 215-988-0080
HEMISPHERX BIOPHARMA INC (Filer) CIK: 0000946644 (see all company filings)

EIN.: 520845822 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-27072 | Film No.: 17845577
SIC: 2836 Biological Products, (No Diagnostic Substances)